Fostemsavir controls viral load in half of people with highly drug-resistant HIV

From aidsmap.com

Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance testing, Max Lataillade of ViiV Healthcare reported at the 16th European AIDS Conference in Milan on Friday.

The findings come from the phase 3 BRIGHTE study carried out in the United States, France and Brazil.

Fostemsavir (formerly BMS-663068) is a new experimental HIV attachment inhibitor which binds to the HIV gp120 protein, preventing HIV attachment to CD4 cells. Other inhibitors of HIV entry, enfuvirtide and maraviroc, have limited roles in HIV treatment. Enfuvirtide is an HIV fusion inhibitor, an injectable agent that is prescribed only for patients with no other treatment options. Maraviroc is a CCR5 antagonist; it prevents HIV from using the CCR5 receptor on the surface of CD4 cells to gain entry to the cell. It is used in treatment-experienced patients.

Fostemsavir is being developed by ViiV Healthcare as an agent for use in treatment-experienced patients with resistance to several classes of antiretroviral drug. The drug was acquired from Bristol-Myers Squibb along with several other experimental antiretroviral drugs in 2016.

Read the full article.

Explore posts in the same categories: HIV care, Research

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: